IMMP - Week In Review: JD Health Raises $3.5 Billion In Hong Kong IPO Climbs 56% On First Day
- JD Health of Guangzhou, the online health-care arm of China e-commerce giant JD.com, completed a $3.5 billion Hong Kong IPO and rose 56% in its first trading session.
- Beijing's Sinovac Biotech reported Sino Biopharma of Hong Kong will invest $515 million in a Sinovac subsidiary to double production of its inactivated COVID-19 vaccine, CoronaVac.
- Suzhou Innovent Biologics has dosed the first patient in a Phase II trial of its CTLA-4 mAb in combination with Tyvyt (sintilimab injection) as a second-line treatment for advanced cervical cancer.
For further details see:
Week In Review: JD Health Raises $3.5 Billion In Hong Kong IPO, Climbs 56% On First Day